Kindred Biosciences (KIN) Reports In-Line Q1 EPS, Revenues Miss

Kindred Biosciences (NASDAQ: KIN) reported Q1 EPS of ($0.24), in-line with the analyst estimate of ($0.24). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $3.45 million.

"We had a strong start to the year, announcing positive results in a new long-acting interleukin-31 antibody program that has the potential to become a best-in-class therapeutic, alongside the acceptance of efficacy data for our parvovirus monoclonal antibody program. With cash runway now through the end of 2023, we are well-positioned to realize the value of our promising late-stage pipeline," said KindredBio's Chief Executive Officer, Richard Chin, M.D.

For earnings history and earnings-related data on Kindred Biosciences (KIN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Reading (RDI) Tops Q2 EPS by 4c